Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The company operates as a vertically integrated pharmaceutical manufacturer with EU GMP certification. It supplies branded products to over 15 countries. Its lead clinical program, TAD®, is currently in Phase III trials evaluating efficacy and safety for preventing myocardial injury in hospitalized pneumonia patients. The company has modernized facilities capable of producing APIs, sterile injectables, lyophilized drugs, vaccines—including mRNA-based—and high containment products. No published results from the ongoing Phase III trial as of January 2025.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biomedica Foscama S.p.A..